文献速递胃肠外科围术期管理与 ERAS

接受袖状胃切除术或Roux-en-Y胃旁路减重/代谢手术患者停用他汀后动脉粥样硬化性心血管疾病事件的风险分层分析

A risk stratification analysis of atherosclerotic cardiovascular disease events post-statin discontinuation in patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass bariatric/metabolic surgeries.
PubMed 文献 · Surgery · 2024-06-19

基于TriNetX数据库2012至2021年69家美国医疗机构的回顾性队列研究,纳入453例接受减重手术且使用他汀的患者,比较停药后动脉粥样硬化性心血管疾病事件风险。一级预防组较二级预防组风险降低82%(HR 0.181,95%CI 0.119-0.274)。西班牙裔/拉丁裔患者风险较高。

要点

  • 减重术后停用他汀,一级预防组1年无事件率93%,二级预防组68%。
  • 一级预防组停他汀后事件风险较二级预防组降低82%(HR 0.181,95%CI 0.119-0.274)。
  • 西班牙裔/拉丁裔患者停他汀后动脉粥样硬化性心血管疾病风险较非西班牙裔/拉丁裔高。

核心结论

  • 减重术后停用他汀可能带来显著风险,尤其对有动脉粥样硬化性心血管疾病病史者及40岁以上合并糖尿病等人群。
  • 结局的种族差异要求个体化、公平的医疗策略。
  • 停用他汀的最佳决策需全面评估心血管决定因素,未来研究对完善治疗策略至关重要。

研究设计与样本

  • 回顾性队列研究,使用TriNetX数据库,涵盖2012至2021年69家美国医疗机构的电子病历。
  • 纳入年龄≥18岁、接受减重手术且同时使用他汀的患者。
  • 停药定义为末次他汀处方后90天空白期。
  • 根据动脉粥样硬化性心血管疾病病史分为一级预防组和二级预防组。
  • 主要结局为停用他汀后发生动脉粥样硬化性心血管疾病事件,采用多变量Cox比例风险模型分析影响因素。

主要发现

  • 453例接受减重手术的他汀使用者中,一级预防组332例(73.1%),二级预防组121例(26.7%)。
  • 术后1年无动脉粥样硬化性心血管疾病事件率:一级预防组93%,二级预防组68%。
  • 一级预防组停用他汀后动脉粥样硬化性心血管疾病事件风险较二级预防组降低82%(HR 0.181,95%CI 0.119-0.274)。
  • 西班牙裔/拉丁裔患者停用他汀后动脉粥样硬化性心血管疾病风险较非西班牙裔/拉丁裔同龄人升高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease remains a leading cause of mortality globally, and its prevalence is notably elevated in individuals with obesity. Bariatric surgery is an effective intervention to reduce obesity-related health risks. However, the implications of discontinuing statin therapy, particularly post-bariatric surgery, among those with a history of atherosclerotic cardiovascular disease have yet to be clarified. We aimed to ascertain the risk of atherosclerotic cardiovascular disease events following statin cessation after bariatric surgery and to delineate the variance in outcomes between primary and secondary prevention cohorts. METHODS: The TriNetX database, encompassing electronic medical records from 69 United States healthcare institutions, spanning 2012 to 2021. Using a retrospective cohort design, patients aged ≥18 years who underwent bariatric surgery and were concurrently on statin therapy were selected. Discontinuation was defined as a 90-day lapse after the last statin prescription. Patients were categorized as "primary" or "secondary" prevention based on their atherosclerotic cardiovascular disease history. The primary outcome was the occurrence of an atherosclerotic cardiovascular disease event post-statin cessation. Multivariable Cox proportional hazards models discerned factors influencing this outcome. RESULTS: Of the 453 statin users who underwent bariatric surgery, 332 (73.1%) were in the primary prevention group and 121 (26.7%) in the secondary prevention group. At 1-year post-surgery, atherosclerotic cardiovascular disease event-free rates were 93% for primary and 68% for secondary prevention groups. Primary prevention patients showed an 82% reduced risk of post-statin cessation atherosclerotic cardiovascular disease events than secondary prevention patients (hazard ratio, 0.181; 95% confidence interval, 0.119-0.274). Additionally, Hispanic/Latino patients had heightened post-statin cessation atherosclerotic cardiovascular disease risks compared to non-Hispanic/Latino peers. CONCLUSION: Post-bariatric surgery statin discontinuation can pose significant risks, especially for those with atherosclerotic cardiovascular disease history and certain demographic groups, such as those over age 40 with diabetes. Ethnic disparities in outcomes necessitate individualized, equitable healthcare strategies. Optimal decisions about statin cessation necessitate comprehensive evaluations of cardiovascular determinants, with future research crucial to refine therapeutic approaches based on these insights.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Alsuhibani AA, Al-Kadi A, Wigle PR, et al. A risk stratification analysis of atherosclerotic cardiovascular disease events post-statin discontinuation in patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass bariatric/metabolic surgeries. Surgery. 2024. PMID: 38902126. doi:10.1016/j.surg.2024.05.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。